https://uthandonethemba.com/2026/07/25/compass-immunotherapy-ai/Uthando Nethembaen2026-07-25T10:42:28+00:00A concept-bottleneck AI predicts immunotherapy response across cancers — but every result is retrospective, and the survival win rests on one sponsor’s own trialbiomarkers, foundation model, clinical AI, immunotherapy, oncology, companion diagnostics, transcriptomicshttps://uthandonethemba.com/2026/07/25/fusion-part2-inertial/Uthando Nethembaen2026-07-24T21:05:15+00:00Inertial confinement and the alternative-concept boom — NIF’s ignition record (target gain 4.13, 2025) is real, but NIF is a weapons-physics facility (negative wall-plug, 2–3 shots/day), not a power path, and the private alternatives each carry an unproven corescience, nuclear fusion, Energy, inertial confinement, NIFhttps://uthandonethemba.com/2026/07/25/fusion-part0-landscape/Uthando Nethembaen2026-07-24T21:02:48+00:00The fusion-energy landscape — NIF’s 2022 ignition (Q_plasma>1) is real, but ignition is not grid electricity; the bottleneck is the outcome layer (Q_engineering, tritium, materials/neutrons, duty cycle, LCOE)science, nuclear fusion, Energy, fusion energyhttps://uthandonethemba.com/2026/07/25/lp-a-part4-outcomes-trials/Uthando Nethembaen2026-07-24T20:56:04+00:00Does lowering Lp(a) actually cut cardiovascular events? The outcome trials — HORIZON, OCEAN(a) and ACCLAIM — and why the first readout is still not incardiovascular disease, science, clinical trials, Lp(a), lipoprotein(a), clinical outcomeshttps://uthandonethemba.com/2026/07/25/lp-a-part2-sirna-aso-pipeline/Uthando Nethembaen2026-07-24T20:54:14+00:00Lowering Lp(a) is a solved problem — the RNA pipeline now competes on durability, not on depthcardiovascular disease, science, clinical trials, siRNA, antisense oligonucleotide, Lp(a), lipoprotein(a)https://uthandonethemba.com/2026/07/25/glp1-part4-skeptic-safety-durability/Uthando Nethembaen2026-07-24T20:52:20+00:00The clinical cost behind the GLP-1 headline — reading lean-mass loss, discontinuation, rebound, and safety signals by evidence tierevidence-based medicine, science, clinical trials, GLP-1, obesity, drug safetyhttps://uthandonethemba.com/2026/07/25/glp1-part3-commercial-landscape/Uthando Nethembaen2026-07-24T20:50:11+00:00The GLP-1 commercial map (Part 3): not “who wins” but “who gets access” — the Novo–Lilly duopoly and the access bottleneckscience, commercialization, GLP-1, obesity, drug pricinghttps://uthandonethemba.com/2026/07/25/glp1-part2-next-gen-pipeline/Uthando Nethembaen2026-07-24T20:44:49+00:00The next-generation obesity pipeline: from “how much you lose” to “at what cost”science, commercialization, clinical trials, GLP-1, incretin, obesityhttps://uthandonethemba.com/2026/07/25/glp1-part1-cv-renal-outcomes/Uthando Nethembaen2026-07-24T20:36:08+00:00Do incretins move hard outcomes in CKM, not just weight? A close read of SELECT, FLOW and SUMMITcardiovascular disease, science, CKM, clinical trials, GLP-1, chronic kidney disease, heart failure